Johnson & Johnson Darzalex first-line treatment of myeloma, the risk of victory is halved December 13, 2017 Source: Sina Pharmaceutical Darson (Daratumumab), a drug belonging to Johnson & Johnson's affiliated Janssen company, was turned to multiple myeloma treatment research very early, and the data obtained by Darzalex may help it win the coveted first-line treatment. At the American Society of Hematology (ASH) annual meeting on Tuesday, the company published the results of a trial showing that Darzalex teamed up with Takeda's Velcade (bortezomib, at halfway through the 16.5-month follow-up period). Bortezomib), melphalan and prednisone (VMP) reduce the risk of disease progression or death in newly diagnosed myeloma patients by 50%. Halving the risk is "you couldn't expect it five years ago," but the results are in line with Yangsen's previous predictions based on the effects of Darzalex. Peter Lebowitz, head of global cancer treatment at Yangsen, said in an interview: "The drug is very active, and we expect to see these results in an earlier situation once we start seeing these results in a relapse. †The way this company looks at it is that this is just the beginning of the drug's move toward first-line medication. "What we are seeing is that this drug seems to be beneficial in combination with any treatment regimen, such as in combination with other IMiD regimens, proteasome regimens... so we generally think this is a mechanism to improve any The result of the set plan," Peter Lebowitz said. Janssen also has a number of ongoing first-line studies in conjunction with other drugs, including one that combines IMiD, a proteasome inhibitor, with Darzalex. He said: "We hope that this compatibility becomes quite common, and you can use this medicine through any solution you choose." Darzalex is the world's first approved CD38-mediated, cytolytic antibody drug that has been approved by the first FDA for multiple myeloma treatment for relapse or progression after third-line therapy. In the same period, Aberdeen, Bristol-Myers Squibb's drug Empliciti (Elotuzumab, elotuzumab) and Takeda's Ninlaro (Ixazomib) were approved for early treatment. But a number of studies by Darzalex helped it quickly catch up with its competitors, and in November 2016 it also made progress in second-line treatment. Yangsen does not intend to stay in the first line of treatment, because it is advancing at an earlier time. In addition, at the ASH meeting, Janssen demonstrated the clinical secondary results of Darzalex in the treatment of smoldering multiple myeloma. Sudden multiple myeloma is a precursor to multiple myeloma, which can put patients at risk of developing more serious diseases. Lebowitz said: "The early stages of the disease are not so complicated, and there is no escape from the treatment mechanism and resistance, so we want to get involved in these diseases earlier," he said. Very good." He added: "The setting of this model has gone beyond the first line and entered an earlier disease situation." (Sina Medical Compilation / Bernardo) Articles, images reference source: ASH: Johnson & Johnson scores big Darzalex win in first-line myeloma, slashing risks in half Squid Food,Frozen Squid,Frozen Squid Tube,Frozen Squid Ring ZHOUSHAN JING YUAN FOOD CO.,LTD , https://www.genho-food.com